Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Forecast and Analysis: Key Insights into Growth, Trends, and Emerging Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Will the Growth Rate of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Shape Industry Trends by 2034?
The market size for inhibitors of sodium glucose cotransporter 2 (SGLT2) has experienced significant expansion in recent times. The prediction is that the market will escalate from a worth of $10.17 billion in 2024 to $11.07 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.8%. Factors leading to this growth during the historical period include successful early clinical trials, escalating regulatory approvals, a rise in the diagnosis rate for diabetes, as well as an increased demand for innovative treatments for diabetes.
Anticipated expansion is on the horizon for the sodium glucose cotransporter 2 (SGLT2) inhibitors market, with projections indicating robust growth in the upcoming years. By 2029, the market size is expected to reach $15.4 billion, with a promising compound annual growth rate (CAGR) of 8.6%. Key factors contributing to this growth during the forecast period include an upward trend in diabetes, escalating obesity levels, heightened awareness about diabetes management, and the application of these inhibitors in the treatment of heart and kidney diseases. The forecast period is also set to witness several emerging trends, such as the use of combination therapies, personalized treatment options, advancements in technology, and traditional drug development.
What External and Internal Drivers Are Contributing to the Growth of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market’s Growth?
Expectations for the sodium glucose cotransporter 2 (SGLT2) inhibitor market’s growth are heightened due to the escalating incidence of diabetes. This metabolic disorder, characterized by elevated blood sugar levels, originates from insulin secretion or insulin action defects, or possibly both. Various factors such as urbanization, stress, environmental pollutants, and inadequate access to healthcare incite a rise in diabetes. Diabetes management employs SGLT2 inhibitors to diminish blood glucose levels by flushing glucose out in urine instead of it being reabsorbed by the kidneys. These inhibitors also provide cardiovascular and renal benefits, proving to be critical for controlling diabetes and its associated complications. As reported by the Australian Bureau of Statistics in December 2023, approximately 5.3% or 1.3 million Australians were found to have diabetes in 2022, with similar rates observed in males (5.8%) and females (4.9%). Diabetes rates exhibit an upward trend, notably spiking with increasing age, amounting to 18.7% among those aged 75 or above. The most prevalent form is Type 2 diabetes, contributing to 87.6% of the cases. Other risk factors include being born overseas, living in disadvantaged areas, and having a disability, which contribute to high diabetes rates. This growing incidence of diabetes consequently propels the sodium glucose cotransporter 2 (SGLT2) inhibitor market’s expansion.
Request Your Free Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp
Who Are the Key Market Players Influencing the Growth of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry?
Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are:
• Pfizer Inc.
• Johnson & Johnson Inc.
• Merck & Co. Inc.
• Bayer AG
• Sanofi S.A.
What Key Market Trends Are Shaping the Future of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry?
Leading firms in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are concentrating their efforts on creating dual inhibitor therapeutic formulas. These are tailored to enhance patient results and control blood sugar levels. Dual inhibitor therapies focus on two distinct sodium-glucose cotransporters (SGLT1 and SGLT2) simultaneously to improve effectiveness in handling afflictions like heart failure and diabetes. For instance, in May 2023, Lexicon Pharmaceuticals Inc., an American biopharmaceutical corporation, got approval from the Food and Drug Administration (FDA) for a medicine for heart failure named sotagliflozin. This pioneering dual inhibitor of sodium-glucose cotransporters 1 and 2 is a daily tablet aimed at lowering cardiovascular mortality, hospital admissions due to heart failure, and urgent heart failure visits in grown-ups dealing with heart failure, type 2 diabetes, chronic kidney disease and other cardiovascular risk factors. It brings about benefits via decreased renal glucose and sodium reabsorption, ultimately lessening preload and afterload and reducing sympathetic activity.
Pre-order Your Report for Quick and Easy Delivery!
Which Industry Segments Are Leading the Development and Expansion of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented –
1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
2) By Route Of Administration: Oral Route, Other Route Of Administration
3) By End User: Hospitals, Homecare Settings, Clinics
Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure
Which Regions Are Emerging as Leaders in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Defines the Scope of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of medications used to treat type 2 diabetes by blocking the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion in urine. This helps lower blood glucose levels and can also contribute to weight loss and reduced blood pressure. They have additional cardiovascular and renal benefits, making them valuable in managing diabetic complications.
Browse Through More Similar Reports By The Business Research Company:
Sodium Benzoate Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/sodium-benzoate-global-market-report
Sodium Lauryl Ether Sulfate [SLES] Global Market Report 2024
Sodium Cocoyl Isethionate Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/sodium-cocoyl-isethionate-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
